NEW YORK (GenomeWeb News) – Agilent Technologies has inked a definitive agreement to acquire Varian for $52 per share, or a total of around $1.5 billion.

The deal will expand Agilent's presence in the life sciences research and applied markets, such as the environment and energy. Agilent said that it also will expand its product portfolio into atomic and molecular spectroscopy and in other fields including nuclear magnetic resonance, imaging, and vacuum technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.